抗抑郁药物相关心血管风险的研究进展

Abstract
Figure/Table
References (32)
Related Citation (15)

Download: PDF (0 KB) HTML (43 KB)
Export: BibTeX | EndNote (RIS)

Abstract Depression incidence rate is high in patients with cardiovascular disease (CVD).Depression increases risks of adverse cardiovascular events including all-cause mortality and cardiovascular disease mortality in patients with CVD.Therefore,it is necessary to treat including drug treatment for CVD patients combined with depression disorder.There are significant differences in the safety and effectiveness of different types of antidepressants in clinical use.In this paper,based on recent clinical researches about different types of antidepressants,it focus on cardiovascular risks associated with the new antidepressants commonly used in patients.The purpose is to help clinicians correctly to choice antidepressants for patients.

Key words： Depression Cardiovascular risks Antidepressants

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Long-fei
	GONG Shan
	YU Guo-long

Cite this article:

WANG Long-fei,GONG Shan,YU Guo-long. Research progress in cardiovascular risk associated with antidepressants[J]. 中国当代医药, 2018, 25(27): 24-27.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I27/24

[1]	Cohen BE，Edmondson D，Kronish IM.State of the art review：depression，stress，anxiety，and cardiovascular disease[J].Am J Hypertens，2015，28（11）：1295-1302.
[2]	Meijer A，Conradi HJ，Bos EH，et al.Prognostic association of depression following myocardial infarction with mortality and cardiovascular events：a meta-analysis of 25 years of research[J].Gen Hosp Psychiatry，2011，33（2）：203-216.
[3]	Pan A，Sun Q，Okereke OI，et al.Depression and risk of stroke morbidity and mortality：a meta-analysis and systematic review[J].JAMA，2011，306（10）：1241-1249.
[4]	Teply RM，Packard KA，White ND，et al.Treatment of depression in patients with concomitant cardiac disease[J].Prog Cardiovasc Dis，2016，58（5）：514-528.
[6]	Thase ME，Larsen KG，Reines E，et al.The cardiovascular safety profile of escitalopram[J].Eur Neuropsychopharmacol 2013，23（11）：1391-1400.
[23]	Feighner JP.Cardiovascular safety in depressed patients：focus on venlafaxine[J].J Clin Psychiatry，1995，56（5）：574-579.
[5]	Nezafati MH，Vojdanparast M，Nezafati P.Antidepressants and cardiovascular adverse events：a narrative review[J].Arya Atheroscler，2015，11（5）：295-304.
[7]	Hanash JA，Hansen BH，Hansen JF，et al.Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome：results from the depression in patients with coronary artery disease（DECARD）trial[J].J Cardiovasc Pharmacol，2012，60（4）：397-405.
[8]	Glassman AH，O'Connor CM，Califf，et al.Sertraline treatment of major depression in patients with acute MI or unstable angina （the SADHART Trial） [J].JAMA，2002，288（6）：701-710.
[9]	Lesperance F，Frasure-Smith N，Koszycki D，et al.Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease：the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy（CREATE）trial[J].JAMA，2007，297（4）：367-379.
[10]	Pizzi C，Rutjes AWS，Costa GM，et al.Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease[J].Am J Cardiol，2011，107（10）：972-979.
[11]	Lichtman JH，Bigger T，Blumenthal H，et al.Depression and coronary heart disease：recommendations for screening，referral，and treatment：a science advisory from the american heart association prevention committee of the council on cardiovascular nursing，council on clinical cardiology，council on epidemiology and prevention，and Interdisciplinary council on quality of care and outcomes research[J].Circulation，2008，118（12）：1768-1775.
[12]	Hamer M，Batty GD，Seldenrijk A，et al.Antidepressant medication use and future risk of cardiovascular disease：the Scottish Health Survey[J].Eur Heart J，2011，32（5）：437-442.
[13]	Wu CS，Tsai YT，Hsiung CA，et al.Comparative risk of ventricular arrhythmia and sudden cardiac death across antidepressants in patients with depressive disorders[J].J Clin Psychopharmacol，2017，37（1）：32-39.
[14]	Jeon SH，Jaekal J，Lee SH，et al.Effects of nortriptyline on QT prolongation：a safety pharmacology study[J].Hum Exp Toxicol，2011，30（10）：1649-1656.
[15]	Waslick BD，Walsh BT，Greenhill LL，et al.Cardiovascular effects of desipramine in children and adults during exercise testing[J].J Am Acad Child Adolesc Psychiatry，1999，38（2）：179-186.
[16]	Robinson DS，Nies A，Corcella J，et al.Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients[J].J Clin Psychiatry，1982，43（5 Pt 2）：8-15.
[17]	Thayssen P，Bjerre M，Kragh-Sorensen P，et al.Cardiovascular effect of imipramine and nortriptyline in elderly patients[J].Psychopharmacology（Berl），1981，74（4）：360-364.
[18]	Hamer M，Batty GD，Seldenrijk A，et al.Antidepressant medication use and future risk of cardiovascular disease：the scottish health Survey[J].Eur Heart J，2011，32（4）：437-442.
[19]	Giardina EG，Barnard T，Johnson L，et al.The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations[J].J Am Coll Cardiol，1986，7（6）：1363-1369.
[20]	Ho JM，Gomes T，Straus SE，et al.Adverse cardiac events in older patients receiving venlafaxine：a population-based study[J].J Clin Psychiatry，2014，75（6）：e552-e558.
[21]	Xue F，Strombom I，Turnbull B，et al.Treatment with duloxetine in adults and the incidence of cardiovascular events[J].J Clin Psychopharmacol，2012，32（1）：23-30.
[22]	Wernicke J，Lledo A，Raskin J，et al.An evaluation of the cardiovascular safety profile of duloxetine：findings from 42 placebocontrolled studies[J].Drug Saf，2007，30 （5）：437-55.
[24]	James WP，Caterson ID，Coutinho W，et al.Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects[J].N Engl J Med，2010，363（10）：905-917.
[25]	Harrison-Woolrych M，Ashton J，Herbison P.Fatal and nonfatal cardiovascular events in a general population prescribed sibutramine in New Zealand：a prospective cohort study[J].Drug Saf，2010，33（7）：605-613.
[26]	Weeke P，Jensen A，Folke F，et al.Antidepressant use and risk of out-of-hospital cardiac arrest：a nationwide casetime-control study[J].Clin Pharmacol Ther，2012，92（1）：72-79.
[27]	Krahn LE，Hanson CA，Pileggi TS，et al.Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia[J].J Clin Psychiatry，2001，62（2）：108-110.
[28]	Service JA，Waring WS.QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone[J].Clin Toxicol（Phila），2008，46（1）：71-73.
[29]	Kemp AH，Quintana DS，Gray MA，et al.Impact of depression and antidepressant treatment on heart rate variability：a review and meta-analysis[J].Biol Psychiatry，2010，67（11）：1067-1074.
[30]	Terhardt J，Lederbogen F，Feuerhack A，et al.Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine[J].Clin Neuropharmacol，2013，36（6）：198-202.
[31]	Rajpurohit N，Aryal SR，Khan MA，et al.Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine：a case of severe drug interaction[J].S D Med，2014，67（4）：137-139.
[32]	Sheline YI，Freedland KE，Carney RM.How safe are serotonin reuptakeinhibitorsfordepression in patients with coronary heart disease?[J].Am J Med，1997，102（1）：54-59.